📰 Network Trials Unit News
Network Trials Unit News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Network Trials Unit. Real-time updates on events, politics, business and more.
July 11, 2023
/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...
September 12, 2022
For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.
September 12, 2022
For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.
April 8, 2022
Washington University conducted several trials of a rare, inherited form of Alzheimer's that typically develops in a person's 50s, 40s...
March 11, 2022
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...
March 11, 2022
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...
March 11, 2022
/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data...
March 11, 2022
/PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data...
March 11, 2022
STOCKHOLM, March 11, 2022 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating
March 16, 2021
Antibody is first of three tau drugs to be evaluated Clinical trial participant Taylor Hutton (left) meets with Randall J. Bateman, MD, director of the global DIAN-TU Alzheimer’s clinical trial in 2018. Hutton’s family has a history of early-onset Alzheimer’s disease. The DIAN-TU is launching three new arms to evaluate experimental Alzheimer’s drugs targeting the protein tau. (Photo: Matt Miller/School of Medicine) March 15, 2021 SHARE A worldwide clinical trial aimed at finding trea...